company background image
CHM

Chimeric TherapeuticsASX:CHM Stock Report

Market Cap

AU$98.4m

7D

10.7%

1Y

n/a

Updated

18 Oct, 2021

Data

Company Financials +
CHM fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

CHM Overview

Chimeric Therapeutics Limited researches, develops, and commercializes cell therapies for cancer in Australia.

Price History & Performance

Summary of all time highs, changes and price drops for Chimeric Therapeutics
Historical stock prices
Current Share PriceAU$0.31
52 Week HighAU$0.24
52 Week LowAU$0.44
Beta0
1 Month Change-4.61%
3 Month Change5.09%
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO5.09%

Recent News & Updates

Shareholder Returns

CHMAU BiotechsAU Market
7D10.7%2.3%0.9%
1Yn/a1.5%20.2%

Return vs Industry: Insufficient data to determine how CHM performed against the Australian Biotechs industry.

Return vs Market: Insufficient data to determine how CHM performed against the Australian Market.

Price Volatility

Is CHM's price volatile compared to industry and market?
CHM volatility
CHM Beta0
Industry Beta1.61
Market Beta1

Stable Share Price: CHM is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: CHM's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2020n/aJennifer Chowhttps://www.chimerictherapeutics.com

Chimeric Therapeutics Limited researches, develops, and commercializes cell therapies for cancer in Australia. The company develops CLTX CAR T cell therapy that is in Phase I clinical study for Glioblastoma; and CDH17 CAR T, which is in preclinical study for neuroendocrine tumours, as well as colorectal, pancreatic, and gastric cancer. It has a strategic partnership with OncoBay Clinical for the development program of CLTX CAR T. The company was incorporated in 2020 and is based in Carlton, Australia.

Chimeric Therapeutics Fundamentals Summary

How do Chimeric Therapeutics's earnings and revenue compare to its market cap?
CHM fundamental statistics
Market CapAU$98.37m
Earnings (TTM)-AU$15.11m
Revenue (TTM)n/a

0x

P/S Ratio

-6.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CHM income statement (TTM)
RevenueAU$0
Cost of RevenueAU$0
Gross ProfitAU$0
ExpensesAU$15.11m
Earnings-AU$15.11m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.045
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.0%

How did CHM perform over the long term?

See historical performance and comparison

Valuation

Is Chimeric Therapeutics undervalued compared to its fair value and its price relative to the market?

4.11x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate CHM's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate CHM's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: CHM is unprofitable, so we can't compare its PE Ratio to the Global Biotechs industry average.

PE vs Market: CHM is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CHM's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CHM is good value based on its PB Ratio (4.1x) compared to the AU Biotechs industry average (4.9x).


Future Growth

How is Chimeric Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

11.5%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if CHM's forecast earnings growth is above the savings rate (1.9%).

Earnings vs Market: Insufficient data to determine if CHM's earnings are forecast to grow faster than the Australian market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if CHM's revenue is forecast to grow faster than the Australian market.

High Growth Revenue: CHM is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if CHM's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Chimeric Therapeutics performed over the past 5 years?

-9,738.4%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: CHM is currently unprofitable.

Growing Profit Margin: CHM is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Unable to establish if CHM's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.

Accelerating Growth: Unable to compare CHM's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CHM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (46.5%).


Return on Equity

High ROE: CHM has a negative Return on Equity (-60.14%), as it is currently unprofitable.


Financial Health

How is Chimeric Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: CHM's short term assets (A$22.7M) exceed its short term liabilities (A$7.4M).

Long Term Liabilities: CHM's short term assets (A$22.7M) exceed its long term liabilities (A$4.0M).


Debt to Equity History and Analysis

Debt Level: CHM is debt free.

Reducing Debt: CHM had no debt 5 years ago.

Debt Coverage: CHM has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: CHM has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Chimeric Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CHM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CHM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CHM's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CHM's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CHM's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.8yrs

Average management tenure


CEO

Jennifer Chow

0.17

Tenure

Ms. Jennifer Chow has been a Director of Chimeric Therapeutics Limited since August 30, 2021. She serves as the Managing Director & Chief Executive Officer of Chimeric Therapeutics Limited since August 30,...


Leadership Team

Experienced Management: CHM's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.


Board Members

Experienced Board: CHM's board of directors are not considered experienced ( 0.5 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: CHM insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: CHM only recently listed within the past 12 months.


Top Shareholders

Company Information

Chimeric Therapeutics Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Chimeric Therapeutics Limited
  • Ticker: CHM
  • Exchange: ASX
  • Founded: 2020
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: AU$98.366m
  • Shares outstanding: 333.44m
  • Website: https://www.chimerictherapeutics.com

Location

  • Chimeric Therapeutics Limited
  • 62 Lygon Street
  • Level 3
  • Carlton
  • Victoria
  • 3053
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/18 07:02
End of Day Share Price2021/10/18 00:00
Earnings2021/06/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.